Patient-derived xenograft (PDX) tumor models have emerged as a new approach to evaluate the effects of cancer drugs on patients' personalized tumor grafts enabling to select the best treatment for the cancer patient and providing a new tool for oncology drug developers. Here, we report that human tumors engrafted in immunodeficient mice are susceptible to formation of B-and T-cell PDX tumors. We xenografted human primary and metastatic tumor samples into immunodeficient mice and found that a fraction of PDX tumors generated from patients' samples of breast, colon, pancreatic, bladder and renal cancer were histologically similar to lymphocytic neoplasms. Moreover, we found that the first passage of breast and pancreatic cancer PDX tumors after initial transplantation of the tumor pieces from the same human tumor graft could grow as a lymphocytic tumor in one mouse and as an adenocarcinoma in another mouse. Whereas subcutaneous PDX tumors resembling human adenocarcinoma histology were slow growing and non-metastatic, we found that subcutaneous PDX lymphocytic tumors were fast growing and formed large metastatic lesions in mouse lymph nodes, liver, lungs, and spleen. PDX lymphocytic tumors were comprised of B-cells which were Epstein-Barr virus positive and expressed CD45 and CD20. Because B-cells are typically present in malignant solid tumors, formation of B-cell tumor may evolve in a wide range of PDX tumor models. Although PDX tumor models show great promise in the development of personalized therapy for cancer patients, our results suggest that confidence in any given PDX tumor model requires careful screening of lymphocytic markers.
Introduction Numerous murine models have been developed to study human cancer [1, 2] . These models are used to investigate the factors involved in malignant transformation, invasion, and metastasis, as well as to examine response to therapy [1, 2] . One of the most widely used models is the human tumor xenograft [1, 2] . The patient-derived xenograft (PDX) tumor model approach is based on the transplantation of primary or metastatic human tumors directly into highly immunodeficient nonobese diabetic/severe combined immunodeficient gamma (NSG) mice followed by continuous propagation of the established heterotopic or orthotopic engraftment in mice [2] [3] [4] . Clinicians can evaluate the effects of cancer drugs on their patients' personalized tumor grafts, enabling them to select the best treatment for the cancer patient, and these models have evolved into a new tool for developers of oncology drugs [2] [3] [4] [5] [6] [7] [8] . However, there are some disadvantages and challenges of using mouse xenograft models. The lack of T-cell immune response in immunodeficient mice makes them vulnerable to T-cell-controlled infections, especially viral infections [9, 10] , as well as to formation of lymphoproliferative lesions [11, 12] . Several recent studies revealed that human tumors engrafted in NSG and NOG (NOD/Shi-scid/IL-2Rγ null ) mice are susceptible to Epstein-Barr virus (EBV)-associated lymphomagenesis [11, 12] . More than 90% of humans are infected with the EBV, and the infection persists for life [13] . EBV, a member of the human herpesvirus family, is the major cause of infectious mononucleosis and is associated with several malignancies including nasopharyngeal carcinoma, gastric carcinoma, Hodgkin lymphoma, Burkitt lymphoma, and posttransplant lymphoma [13, 14] . EBV can infect human B-cells, T-cells, NK cells, and epithelial cells [15] . Because B-cells are typically present in malignant solid tumors, formation of EBV-associated B-cell PDX tumor may evolve in a wide range of PDX tumor models.
Here, we report that 32% of PDX tumors generated from the given patient-derived tumor sample (including breast, colon, pancreatic, bladder, and renal cancer) can progress into EBV-positive and highly metastatic lymphocytic tumors. Our results suggest that human solid tumors engrafted in NSG mice are susceptible to formation of B-and T-cell PDX tumors and that thorough testing for lymphocytic markers should be performed to ensure that the appropriate PDX tumor model is used for the identification of personalized therapy for each patient.
Materials and Methods
The research protocol was approved by Northwestern University institutional review board, and all patients provided appropriate informed consent. Human tumor tissue samples were obtained from cancer patients and deidentified with six-digit numbers (Northwestern University Pathology Core Facility [PCF] number). Freshly resected human tumor samples were transplanted subcutaneously (SC) into NSG mice. Histopathological evaluation of tumor samples was performed by board-certified pathologists (S.R. and J.W.). When SC PDX tumor reached 1.5 cm in its largest dimension, the mouse was euthanized. Subcutaneous PDX tumor and mouse spleen, lymph nodes (LN), liver, and lung were collected; fixed in 10% formalin; and processed for paraffin embedding. Paraffin sections (5 μm) were stained with hematoxylin and eosin (H&E) for initial histopathological evaluation. For immunohistochemical (IHC) staining, we used antibodies against the leukocyte common antigen CD45 (monoclonal mouse anti-human, final concentration 5 μg/ml; Dako, Carpinteria, CA), B-cell specific surface protein CD20 (monoclonal mouse anti-human, final concentration 0.63 μg/ml; Dako, Carpinteria, CA), pan-T-cell specific marker CD3 (polyclonal rabbit anti-human, final concentration 6 μg/ml; Dako, Carpinteria, CA), and epithelial cell pan-cytokeratin (monoclonal mouse anti-human, final concentration 0.5 μg/ml; Thermo Scientific, Fremont, CA). IHC staining was visualized with Dako Envision +/ HRP kit according to the manufacturer's recommended procedure. In situ hybridization (ISH) for EBV-encoded RNA (EBER) was performed on a Ventana Medical Systems automated slide stainer using EBER probes and the Ventana ISH iVIEW Blue Detection Kit according to manufacturer's instructions.
Results
We established PDX tumors in NSG mice by SC transplantation of freshly resected tumors obtained from breast, colon, pancreatic, bladder, and renal cancer patients. At the first passage of PDX tumor, we found that a fraction of PDX tumors generated from patient samples of breast (one of three cases), colon (two of seven cases), pancreatic (one of five cases), bladder (one of two cases), and renal (one of two cases) cancer was histologically similar to lymphocytic neoplasm (Figures 1-5 ). We found that 15 of 22 (68%) PDX tumors (generated from patients' samples of breast, colon, pancreatic, bladder, and renal cancer) resembled histopathological characteristics of original human carcinoma, whereas 7 of 22 (32%) PDX tumors were comprised of lymphocyte-like cells. Some of SC lymphocytic PDX tumors had rare inclusions of carcinoma cells. Histologically, we found proliferation of a mixed population of mononuclear cells, ranging from small lymphocytes or plasma cells to large atypical lymphoid cells with pleomorphic nuclei and abundant basophilic cytoplasm resembling lymphoblastoid cells, in lymphocytic SC and metastatic PDX tumors ( Figures 2, 4 , and 5). Strikingly, whereas SC PDX tumors resembling primary human carcinoma histology were slow growing and nonmetastatic, we found that SC lymphocytic PDX tumors were fast growing and formed large metastatic lesions in mouse spleen, lymph nodes, liver, and lung ( Figure 1 ; Table 1 ). To differentiate between poorly differentiated carcinoma and lymphocytic PDX tumor, we immunophenotyped lymphocytic-like PDX tumors using immunohistochemical staining for analysis of cytokeratin, CD45, CD20, and CD3 expression and ISH for detection of EBV (EBER). Because EBV does not infect rodent cells [16] , EBER-positive staining was used as a marker of infected human cells in mouse tissue. Immunohistochemical staining showed that both human leukocyte common antigen CD45 and B-cell antigen CD20 were expressed in EBER-positive lymphocytic cells in 6 of 7 lymphoid PDX tumors and corresponding metastatic lesions (Figures 4 and 5 ; Supplementary Figures 1-3 ). Our findings of EBER-positive staining in lymphocytic PDX tumors suggest that EBV-associated lymphomagenesis may lead to development of human B-cell PDX tumors from xenografted human carcinomas because of the high prevalence of EBV in humans and the presence of EBV-infected B cells in solid human tumors.
In one case, we found that the first passage of breast PDX tumor (PCF #373342) grew as an EBER-positive lymphocytic neoplasm in one mouse and as a poorly differentiated adenocarcinoma in another mouse after initial subcutaneous transplantation of the same sample of metastatic pleural effusion obtained from a breast cancer patient (Table 1; Figure 3A) . B-cell origin of lymphocytic PDX tumor (PCF #373342) was confirmed by IHC staining showing that lymphocytic cells were cytokeratin negative, CD45 positive, and CD20 positive (Table 1 ; Figure 4 ). The growth of the SC lymphocytic PDX tumor (PCF #373342) led to development of lymph node, lung, and liver metastases, whereas the adenocarcinoma PDX from this same patient's pleural effusion did not metastasize (Table 1; Figure 4) . cytokeratin negative, CD45 positive, CD20 negative, and CD3 positive (Table 1; Figure 5B ). T-and B-cell PDX tumors (PCF #379419) developed distant metastases in mouse lung (T-cell), liver (B-cell), and spleen (B-cell) (Figure 1 ; Table 1 ). Because of the small inclusions of pancreatic carcinoma cells in the B-cell SC PDX tumor (PCF #379419), further SC retransplantation of this tumor in nude mouse led to the eventual development of a pancreatic PDX tumor resembling moderately differentiated adenocarcinoma ( Figure 3B ). Thus, retransplantation of SC B-cell PDX tumor from NSG to nude mouse helps to clear SC PDX tumor from EBV-positive B cells leading to formation of carcinoma ( Figure 3B ). Furthermore, we found that PDX lymphocytic tumors did not grow in nude mice after retransplantation from NSG mice. In nude mice, we observed that PDX tumors could grow only as carcinomas. Probably, this phenomenon can be explained by the fact that nude mice maintain NK cells (participate in the immune response to EBV) which are not available in highly immunodeficient NSG mice.
We found that the morphology and immunophenotype of tumor cells in the metastatic lymphoid tumors corresponded to those found in SC lymphocytic PDX tumors: EBER positive, CD45 positive, CD20 positive and EBER negative, CD45 positive, CD20 negative, CD3 positive in B-and T-cell PDX tumors, respectively (Table 1 ; Figures 4 and 5) . We found that EBER-positive metastatic PDX B-cells could completely replace benign cells in mouse spleen, whereas the foci of liver metastasis ranged from small periportal lesions to diffuse infiltration lesions that altered hepatic histological architecture (Figures 4 and 5 ; Supplementary Figures 1 and 2 ). We revealed that mice with small lymphocytic metastases in the liver did not show metastatic tumors in lung. Our findings also demonstrate that mouse spleen is likely the most affected organ by the dissemination of lymphoid metastatic cells from SC lymphocytic PDX tumor.
Our results suggest that PDX tumors engrafted in immunodeficient NSG mice are susceptible to formation of aggressive and metastatic lymphocytic PDX tumors and that thorough testing for lymphocytic markers should be performed to ensure that appropriate PDX tumor model is used for the identification of personalized therapy for each patient. 
Discussion
Although the use of immunodeficient mice contributes to better efficiency of human tumor xenotransplantation [2] , establishing PDX tumor models in NSG mice has presented some challenges and limitations. The lack of an intact immune system affects tumor growth as well as metastasis [17] . The lack of T-cell immune response in immunodeficient mice makes them vulnerable to T-cell-controlled infections, especially viral infections [9, 10] . It has been reported that T-cells play a prominent role in controlling EBV-associated oncogenesis [18] . Most people are infected with EBV [15] . Because EBV can infect human B-cells and T-cells which are typically present in solid malignant tumor [19] , EBV-associated lymphocytic PDX tumors may develop as a result of xenotransplantation of human solid tumor to immunodeficient mice [11, 12] . The potential development of lymphocytic PDX tumors instead of an expected carcinoma may significantly affect or mislead the efforts of clinicians to evaluate the effects of cancer drugs on a particular patient's tumor grafts, leading to the selection of inappropriate clinical treatments for that patient.
Our study demonstrates that PDX tumor (developed from patient samples of breast, colon, pancreatic, bladder, and renal cancer) progressed to highly metastatic lymphocytic PDX tumor in 7 of 22 (32%) cases after initial SC transplantation of human tumor samples in NSG mice. Our results are supported by a recently published study demonstrating the development of EBV-associated B-cell PDX tumors in 11 of 21 xenografts generated in NSG mice from 16 independent patient tumor samples of hepatocellular carcinoma [12] . However, subcutaneous B-cell PDX tumors in that study were not metastatic in NSG mice [12] . Our results demonstrate that SC lymphocytic PDX tumors are fast growing and form large metastatic lesions in NSG mouse spleen, lymph nodes, liver, and lung. In contrast to SC lymphocytic PDX tumors, we found that SC PDX tumors resembling primary human carcinoma histology were slow growing and nonmetastatic. These findings suggest that metastatic lesions in lymph nodes, spleen, lung, or liver could serve as potential markers of growing lymphocytic but not carcinoma PDX tumor after initial SC transplantation of human tumor sample.
Our results show that EBV-associated lymphocytic PDX tumors may be developed in NSG mice after initial transplantation of a wide range of human carcinomas (breast, colon, pancreatic, bladder, and renal). Another recently published study has demonstrated the development of EBV-associated lymphocytic PDX tumors from colorectal, gastric, breast, and lung tumor samples transplanted SC to NOG mice [11] . In established PDX tumor models, the incidence of lymphocytic PDX tumors was 56% (19 of 33), 76% (13 of 17), 50% (2 of 4), and 67% (4 of 6) after initial transplantation of human colorectal, gastric, breast, and lung tumors in NOG mice, respectively [11]. Histopathologically, Fujii et al. found lymphocytic metastatic lesions in mouse spleen (all mice), liver, and kidney (1 of 6 mice) obtained from six NOG mice which developed SC lymphocytic PDX tumors after initial transplantation of human colorectal tumor samples [11] .
Here, we also report the development of a T-cell PDX tumor after initial transplantation of a human pancreatic carcinoma sample to NSG mice. Our findings suggest that lymphocytic PDX tumors not only are represented by EBV-associated B-cell tumors but may also originate from EBV-negative T-cells (CD45 positive, CD3 positive, CD20 negative). We found that lymphocytic PDX tumors can form hematogenous (spleen, liver, and lung) and lymphogenous (lymph node) metastases (Table 1) . However, the formation of SC and metastatic T-cell PDX lesions might also reflect xenogeneic graft versus host disease. A previous study described polyclonal disease-unrelated cotransplanted donor human T-lymphocyte expansion in NSG recipient mice [20] . In one study, donor T-cells mediated xenogeneic graft versus host disease and masked the engraftment of human AML in mice [20] . Other studies demonstrated significant accumulation of donor T-cells in spleen, whereas expression of homing receptors could direct T-cells to skin [21] , lung [22] , and liver [23, 24] .
In conclusion, our results suggest that human tumors engrafted in NSG mice are susceptible to formation of lymphocytic PDX tumors and emphasize the need for thorough testing for lymphocytic markers to ensure that the appropriate (nonlymphocytic) PDX tumor model is used for the identification of personalized therapy for cancer patients.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.neo.2015.09.004. 
